diazoxide has been researched along with Diabetes Mellitus, Adult-Onset in 42 studies
Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.
diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The patient received treatment with oral diazoxide and continuous glucose monitoring (CGM), which resulted in the resolution of the hypoglycemia." | 7.81 | Insulinoma in a patient with chronic renal failure due to type 2 diabetes mellitus treated effectively with diazoxide. ( Aso, Y; Hiraishi, H; Kojima, M; Shimizu, M; Suzuki, K; Tsuchida, K, 2015) |
| "DZX promoted the incidence of arrhythmias, because all DZX-treated T2DM hearts exhibited ischemia-induced VTs that persisted on reperfusion." | 5.42 | The Classically Cardioprotective Agent Diazoxide Elicits Arrhythmias in Type 2 Diabetes Mellitus. ( Akar, FG; Hu, J; Karam, BS; Motloch, LJ; Xie, C, 2015) |
| "Diazoxide appears to cause post-receptor insulin resistance in NIDDM, and it may be a useful tool for studying post-receptor binding events." | 5.27 | Post-receptor insulin resistance after diazoxide in non-insulin dependent diabetes. ( Greenwood, RH; Hales, CN; Olczak, SA, 1986) |
| " The patient received treatment with oral diazoxide and continuous glucose monitoring (CGM), which resulted in the resolution of the hypoglycemia." | 3.81 | Insulinoma in a patient with chronic renal failure due to type 2 diabetes mellitus treated effectively with diazoxide. ( Aso, Y; Hiraishi, H; Kojima, M; Shimizu, M; Suzuki, K; Tsuchida, K, 2015) |
| "Right atrial sections from four patient groups-non-diabetic, insulin-dependent diabetes mellitus (IDDM), non-insulin-dependent diabetes mellitus (NIDDM) receiving glibenclamide, and NIDDM receiving metformin-were subjected to one of the following protocols: aerobic control, simulated ischemia/reoxygenation, ischemic preconditioning before ischemia, and pharmacological preconditioning with alpha 1 agonist phenylephrine, adenosine, the mito-K(ATP) channel opener diazoxide, the protein kinase C (PKC) activator phorbol-12-myristate-13-acetate (PMA), or the p38 mitogen-activated protein kinase (p38MAPK) activator anisomycin." | 3.73 | Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. ( Fowler, A; Galiñanes, M; Hassouna, A; Loubani, M; Matata, BM; Standen, NB, 2006) |
| "Diazoxide was initiated in 46 children (46/67-69%); responsiveness was found in 91% (42/46)." | 2.82 | Variable phenotypes of individual and family monogenic cases with hyperinsulinism and diabetes: a systematic review. ( Nicolino, M; Perge, K, 2022) |
| "Treatment with diazoxide did not incur any increase in bedtime insulin." | 2.71 | Nine weeks of bedtime diazoxide is well tolerated and improves beta-cell function in subjects with Type 2 diabetes. ( Grill, V; Kollind, M; Qvigstad, E, 2004) |
| "Therefore, glibenclamide treatment of Type 2 diabetes mellitus may have hazardous cardiovascular effects when used under conditions of ischaemia." | 2.70 | Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients. ( Abbink, EJ; Jansen van Rosendaal, A; Lutterman, JA; Pickkers, P; Russel, FG; Smits, P; Tack, CJ, 2002) |
| "Fourteen patients with NIDDM received metformin or glibenclamide for 1 month in a double-blind, randomized crossover study." | 2.68 | Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM. ( Daher, A; Diamond, T; Howes, LG; Lykos, D; Morris, R; Sundaresan, P, 1997) |
| "Diazoxide was commenced in 28 patients (82." | 1.72 | Clinical and genetic heterogeneity of HNF4A/HNF1A mutations in a multicentre paediatric cohort with hyperinsulinaemic hypoglycaemia. ( Brusgaard, K; Christesen, H; Conlon, N; Dastamani, A; Demirbilek, H; Flanagan, SE; Gubaeva, D; Houghton, JAL; McGlacken-Byrne, SM; Melikyan, M; Mohammad, JK; Murphy, NP; Schou, AJ; Shah, P; Siersbæk, J, 2022) |
| "The therapeutic success of peptidic GLP-1 receptor agonists for treatment of type 2 diabetes mellitus (T2DM) motivated our search for orally bioavailable small molecules that can activate the GLP-1 receptor (GLP-1R) as a well-validated target for T2DM." | 1.56 | Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R). ( Breitschopf, K; Defossa, E; Kurz, M; Lebreton, S; Li, Z; Lohmann, M; Löhn, M; Matter, H; Méndez, M; Mors, H; Podeschwa, M; Rackelmann, N; Riedel, J; Safar, P; Schäfer, M; Thorpe, DS; Weitz, D, 2020) |
| "This diet induces a type 2 diabetes/metabolic syndrome phenotype with hypertension." | 1.48 | Characterization of vascular dysregulation in meriones shawi after high-calorie diet feeding. ( Cherkaoui-Tangi, K; Lyoussi, B; Morel, N; Wibo, M, 2018) |
| "DZX promoted the incidence of arrhythmias, because all DZX-treated T2DM hearts exhibited ischemia-induced VTs that persisted on reperfusion." | 1.42 | The Classically Cardioprotective Agent Diazoxide Elicits Arrhythmias in Type 2 Diabetes Mellitus. ( Akar, FG; Hu, J; Karam, BS; Motloch, LJ; Xie, C, 2015) |
| "Desflurane (6%) was administered during the first 5 min of reoxygenation either alone or in the presence of calphostin C (PKC inhibitor) or 5-hydroxydecanoate (5-HD) (mitoK(ATP) channel antagonist)." | 1.37 | Mechanisms involved in the desflurane-induced post-conditioning of isolated human right atria from patients with type 2 diabetes. ( Buléon, C; Galera, P; Gérard, JL; Hanouz, JL; Lemoine, S; Massetti, M; Zhu, L, 2011) |
| "Type 2 diabetes is characterized by impaired beta-cell secretory function, insulin resistance, reduced high-density lipoprotein (HDL) levels, and increased cardiovascular risk." | 1.36 | Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. ( Appavoo, M; Barter, PJ; Fryirs, MA; Heather, AK; Rye, KA; Tabet, F; Tuch, BE, 2010) |
| "Although insulinoma is rare in the elderly and exceedingly rare in the context of type 2 diabetes, it should be given due consideration when no other exacerbating factor is found." | 1.33 | A mysterious case of normalising blood sugar: insulinoma in a long-standing diabetic patient. ( Hameed, MF; Hoyle, GE; Muir, Z, 2006) |
| "Psammomys obesus is a model of type 2 diabetes that displays resistance to insulin and deranged beta-cell response to glucose." | 1.31 | Defective stimulus-secretion coupling in islets of Psammomys obesus, an animal model for type 2 diabetes. ( Cerasi, E; Efendic, S; Kaiser, N; Khan, A; Nesher, R; Warwar, N, 2001) |
| "The diazoxide-mediated increase in the forearm blood flow ratio (infused/control arm) was significantly less pronounced after glibenclamide than after acarbose (290 +/- 58% and 561 +/- 101% respectively; P<0." | 1.31 | Vascular K(ATP) channel blockade by glibenclamide, but not by acarbose, in patients with Type II diabetes. ( Abbink, EJ; Lutterman, JA; Pickkers, P; Russel, FG; Smits, P; Tack, CJ; van Rosendaal, AJ, 2002) |
| "Diazoxide was added to culture medium to block glucose-induced insulin secretion and thus investigate the importance of overstimulation." | 1.30 | Enhancing effects of long-term elevated glucose and palmitate on stored and secreted proinsulin-to-insulin ratios in human pancreatic islets. ( Björklund, A; Grill, V, 1999) |
| "The GK rat is a spontaneous model of NIDDM." | 1.29 | Impaired coupling of glucose signal to the exocytotic machinery in diabetic GK rats: a defect ameliorated by cAMP. ( Abdel-Halim, SM; Berggren, PO; Efendić, S; Guenifi, A; Khan, A; Larsson, O; Ostenson, CG, 1996) |
| "Diazoxide appears to cause post-receptor insulin resistance in NIDDM, and it may be a useful tool for studying post-receptor binding events." | 1.27 | Post-receptor insulin resistance after diazoxide in non-insulin dependent diabetes. ( Greenwood, RH; Hales, CN; Olczak, SA, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.38) | 18.7374 |
| 1990's | 12 (28.57) | 18.2507 |
| 2000's | 16 (38.10) | 29.6817 |
| 2010's | 10 (23.81) | 24.3611 |
| 2020's | 3 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Méndez, M | 1 |
| Matter, H | 1 |
| Defossa, E | 1 |
| Kurz, M | 1 |
| Lebreton, S | 1 |
| Li, Z | 1 |
| Lohmann, M | 1 |
| Löhn, M | 1 |
| Mors, H | 1 |
| Podeschwa, M | 1 |
| Rackelmann, N | 1 |
| Riedel, J | 1 |
| Safar, P | 1 |
| Thorpe, DS | 1 |
| Schäfer, M | 1 |
| Weitz, D | 1 |
| Breitschopf, K | 1 |
| McGlacken-Byrne, SM | 1 |
| Mohammad, JK | 1 |
| Conlon, N | 1 |
| Gubaeva, D | 1 |
| Siersbæk, J | 1 |
| Schou, AJ | 1 |
| Demirbilek, H | 1 |
| Dastamani, A | 1 |
| Houghton, JAL | 1 |
| Brusgaard, K | 1 |
| Melikyan, M | 1 |
| Christesen, H | 1 |
| Flanagan, SE | 1 |
| Murphy, NP | 1 |
| Shah, P | 1 |
| Perge, K | 1 |
| Nicolino, M | 1 |
| Lyoussi, B | 1 |
| Cherkaoui-Tangi, K | 1 |
| Morel, N | 1 |
| Wibo, M | 1 |
| Shimizu, M | 1 |
| Suzuki, K | 1 |
| Tsuchida, K | 1 |
| Kojima, M | 1 |
| Hiraishi, H | 1 |
| Aso, Y | 1 |
| Zhou, Y | 1 |
| Sun, P | 1 |
| Wang, T | 1 |
| Chen, K | 1 |
| Zhu, W | 1 |
| Wang, H | 1 |
| Fatehi, M | 1 |
| Carter, CR | 1 |
| Youssef, N | 1 |
| Hunter, BE | 1 |
| Holt, A | 1 |
| Light, PE | 1 |
| Nelson, BW | 1 |
| Van Wagoner, DR | 1 |
| Xie, C | 1 |
| Hu, J | 1 |
| Motloch, LJ | 1 |
| Karam, BS | 1 |
| Akar, FG | 1 |
| Esterson, YB | 1 |
| Carey, M | 1 |
| Boucai, L | 1 |
| Goyal, A | 1 |
| Raghavan, P | 1 |
| Zhang, K | 1 |
| Mehta, D | 1 |
| Feng, D | 1 |
| Wu, L | 1 |
| Kehlenbrink, S | 1 |
| Koppaka, S | 1 |
| Kishore, P | 1 |
| Hawkins, M | 1 |
| Grill, V | 5 |
| Radtke, M | 2 |
| Qvigstad, E | 3 |
| Kollind, M | 3 |
| Björklund, A | 4 |
| Fryirs, MA | 1 |
| Barter, PJ | 1 |
| Appavoo, M | 1 |
| Tuch, BE | 1 |
| Tabet, F | 1 |
| Heather, AK | 1 |
| Rye, KA | 1 |
| Lemoine, S | 1 |
| Zhu, L | 1 |
| Buléon, C | 1 |
| Massetti, M | 1 |
| Gérard, JL | 1 |
| Galera, P | 1 |
| Hanouz, JL | 1 |
| Lehner, Z | 1 |
| Stadlbauer, K | 1 |
| Adorjan, I | 1 |
| Rustenbeck, I | 1 |
| Belz, M | 1 |
| Fenzl, A | 1 |
| de Cillia, VA | 1 |
| Gruber, D | 1 |
| Bauer, L | 1 |
| Frobel, K | 1 |
| Brunmair, B | 1 |
| Luger, A | 1 |
| Fürnsinn, C | 1 |
| Guldstrand, M | 1 |
| Lins, PE | 1 |
| Adamson, U | 1 |
| Bränström, R | 1 |
| Aspinwall, CA | 1 |
| Välimäki, S | 1 |
| Ostensson, CG | 1 |
| Tibell, A | 1 |
| Eckhard, M | 1 |
| Brandhorst, H | 1 |
| Corkey, BE | 1 |
| Berggren, PO | 2 |
| Larsson, O | 2 |
| Alemzadeh, R | 2 |
| Tushaus, KM | 1 |
| Tushaus, K | 1 |
| Hassouna, A | 1 |
| Loubani, M | 1 |
| Matata, BM | 1 |
| Fowler, A | 1 |
| Standen, NB | 1 |
| Galiñanes, M | 1 |
| Hansen, JB | 1 |
| Hameed, MF | 1 |
| Hoyle, GE | 1 |
| Muir, Z | 1 |
| Huang, Q | 1 |
| Bu, S | 1 |
| Yu, Y | 1 |
| Guo, Z | 1 |
| Ghatnekar, G | 1 |
| Bu, M | 1 |
| Yang, L | 1 |
| Lu, B | 1 |
| Feng, Z | 1 |
| Liu, S | 1 |
| Wang, F | 1 |
| Hoa, NK | 1 |
| Norberg, A | 1 |
| Sillard, R | 1 |
| Van Phan, D | 1 |
| Thuan, ND | 1 |
| Dzung, DT | 1 |
| Jörnvall, H | 1 |
| Ostenson, CG | 3 |
| Sato, Y | 3 |
| Aizawa, T | 3 |
| Taguchi, N | 2 |
| Ishihara, F | 3 |
| Hashizume, K | 3 |
| Nakabayashi, T | 1 |
| Kobuchi, H | 1 |
| Hidaka, H | 1 |
| Nagasawa, T | 1 |
| Itoh, N | 1 |
| Abdel-Halim, SM | 1 |
| Guenifi, A | 1 |
| Khan, A | 2 |
| Efendić, S | 2 |
| Malaisse, WJ | 1 |
| Lebrun, P | 1 |
| Pirotte, B | 1 |
| Van Poelje, PD | 1 |
| Viñambres, C | 1 |
| Villanueva-Peñacarrillo, ML | 1 |
| Valverde, I | 1 |
| Gäbel, J | 1 |
| Rorsman, P | 1 |
| Grill, VE | 1 |
| Sundaresan, P | 3 |
| Lykos, D | 3 |
| Daher, A | 3 |
| Diamond, T | 3 |
| Morris, R | 3 |
| Howes, LG | 3 |
| Harvey, J | 1 |
| Ashford, ML | 1 |
| Spiller, HA | 1 |
| Nesher, R | 1 |
| Warwar, N | 1 |
| Cerasi, E | 1 |
| Kaiser, N | 1 |
| Itabashi, N | 1 |
| Okada, K | 1 |
| Muto, S | 1 |
| Fujita, N | 1 |
| Ohta, T | 1 |
| Asano, Y | 1 |
| Saito, T | 1 |
| Abbink, EJ | 2 |
| Pickkers, P | 2 |
| van Rosendaal, AJ | 1 |
| Lutterman, JA | 2 |
| Tack, CJ | 2 |
| Russel, FG | 2 |
| Smits, P | 2 |
| Jansen van Rosendaal, A | 1 |
| Olczak, SA | 1 |
| Greenwood, RH | 1 |
| Hales, CN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gynostemma Pentaphyllum Tea Improves Insulin Sensitivity in Type 2 Diabetic Patients[NCT01254084] | Phase 1/Phase 2 | 16 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| Anti-Diabetic Effect of Gynostemma Pentaphyllum Tea as add-on Therapy With Sulfonylureas in Type 2 Diabetic Patients[NCT00808860] | Phase 1/Phase 2 | 25 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Anti-diabetic Effect of Gynostemma Pentaphyllum Tea in Type 2 Diabetic Patients[NCT00786500] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for diazoxide and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Variable phenotypes of individual and family monogenic cases with hyperinsulinism and diabetes: a systematic review.
Topics: Child; Congenital Hyperinsulinism; Diabetes Mellitus, Type 2; Diazoxide; Female; Humans; Mutation; P | 2022 |
Beneficial effects of K-ATP channel openers in diabetes: an update on mechanisms and clinical experiences.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diazoxide; Humans; Hypoglycemic Agents; Insuli | 2009 |
Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives.
Topics: Amides; Animals; ATP-Binding Cassette Transporters; Benzopyrans; Benzothiadiazines; Congenital Hyper | 2006 |
8 trials available for diazoxide and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Central Regulation of Glucose Production May Be Impaired in Type 2 Diabetes.
Topics: Animals; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Diazoxide; Female; Glucose; G | 2016 |
Improved beta cell function after short-term treatment with diazoxide in obese subjects with type 2 diabetes.
Topics: Antihypertensive Agents; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, LDL; Diabetes Mellitus; | 2002 |
Nine weeks of bedtime diazoxide is well tolerated and improves beta-cell function in subjects with Type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diazoxide; Double-Blind Method; Drug Administration Schedu | 2004 |
Twelve weeks' treatment with diazoxide without insulin supplementation in Type 2 diabetes is feasible but does not improve insulin secretion.
Topics: Carbamates; Diabetes Mellitus, Type 2; Diazoxide; Dose-Response Relationship, Drug; Female; Humans; | 2007 |
Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM.
Topics: Acetylcholine; Adult; Aged; Angiotensin II; Blood Glucose; Blood Pressure; Cholesterol; Cross-Over S | 1997 |
Acute effects of oral glibenclamide on blood pressure and forearm vascular resistance in diabetics.
Topics: Adenosine Triphosphate; Adult; Aged; Blood Glucose; Blood Pressure; Cross-Over Studies; Diabetes Mel | 1997 |
Acute effects of oral glibenclamide on blood pressure and forearm vascular resistance in diabetics.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Diazoxide | 1998 |
Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.
Topics: Acetylcholine; Adult; Aged; Blood Flow Velocity; Blood Pressure; Body Mass Index; Body Weight; C-Pep | 2002 |
31 other studies available for diazoxide and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R).
Topics: Allosteric Regulation; Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Drug Desi | 2020 |
Clinical and genetic heterogeneity of HNF4A/HNF1A mutations in a multicentre paediatric cohort with hyperinsulinaemic hypoglycaemia.
Topics: Adolescent; Birth Weight; Child; Child, Preschool; Cohort Studies; Diabetes Mellitus, Type 1; Diabet | 2022 |
Characterization of vascular dysregulation in meriones shawi after high-calorie diet feeding.
Topics: Animals; Aorta; Arginine; Carbachol; Diabetes Mellitus, Type 2; Diazoxide; Endothelium, Vascular; En | 2018 |
Insulinoma in a patient with chronic renal failure due to type 2 diabetes mellitus treated effectively with diazoxide.
Topics: Antihypertensive Agents; Biomarkers, Tumor; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dia | 2015 |
Inhibition of Calcium Influx Reduces Dysfunction and Apoptosis in Lipotoxic Pancreatic β-Cells via Regulation of Endoplasmic Reticulum Stress.
Topics: Animals; Apoptosis; Calcium Signaling; Cell Line, Tumor; Diabetes Mellitus, Type 2; Diazoxide; Endop | 2015 |
Molecular determinants of ATP-sensitive potassium channel MgATPase activity: diabetes risk variants and diazoxide sensitivity.
Topics: Amino Acid Substitution; Diabetes Mellitus, Type 2; Diazoxide; HEK293 Cells; Humans; Mutation, Misse | 2015 |
How Does Diazoxide Elicit Arrhythmias in Rats With Type 2 Diabetes?: Is This Effect Clinically Significant?
Topics: Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Diabetes Mellitus, Type 2; Diazoxide; Male | 2015 |
The Classically Cardioprotective Agent Diazoxide Elicits Arrhythmias in Type 2 Diabetes Mellitus.
Topics: Animals; Arrhythmias, Cardiac; Cardiotonic Agents; Diabetes Mellitus, Type 2; Diazoxide; Disease Mod | 2015 |
Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion.
Topics: Animals; Apolipoprotein A-I; Apolipoprotein A-II; ATP Binding Cassette Transporter 1; ATP Binding Ca | 2010 |
Mechanisms involved in the desflurane-induced post-conditioning of isolated human right atria from patients with type 2 diabetes.
Topics: Aged; Anesthetics, Inhalation; Blotting, Western; Decanoic Acids; Desflurane; Diabetes Mellitus, Typ | 2011 |
Mechanisms of antihyperglycaemic action of efaroxan in mice: time for reappraisal of α2A-adrenergic antagonism in the treatment of type 2 diabetes?
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antihypertensive Age | 2012 |
Long-chain CoA esters activate human pancreatic beta-cell KATP channels: potential role in Type 2 diabetes.
Topics: Acyl Coenzyme A; Adenosine Diphosphate; Adenosine Triphosphate; Diabetes Mellitus, Type 2; Diazoxide | 2004 |
Modulation of adipoinsular axis in prediabetic zucker diabetic fatty rats by diazoxide.
Topics: Adenylyl Cyclases; Adiponectin; Adipose Tissue; Animals; Blood Glucose; Body Weight; Diabetes Mellit | 2004 |
Diazoxide attenuates insulin secretion and hepatic lipogenesis in zucker diabetic fatty rats.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Body Weight; Diabetes Mellitus, Type 2; Diazo | 2005 |
Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium.
Topics: Adenosine; Adrenergic alpha-Agonists; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitu | 2006 |
A mysterious case of normalising blood sugar: insulinoma in a long-standing diabetic patient.
Topics: Aged; Diabetes Mellitus, Type 2; Diazoxide; Female; Humans; Hypoglycemia; Insulinoma; Vasodilator Ag | 2006 |
Diazoxide prevents diabetes through inhibiting pancreatic beta-cells from apoptosis via Bcl-2/Bax rate and p38-beta mitogen-activated protein kinase.
Topics: Animals; Antihypertensive Agents; Apoptosis; Area Under Curve; bcl-2-Associated X Protein; Blood Glu | 2007 |
The possible mechanisms by which phanoside stimulates insulin secretion from rat islets.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cyclic AMP-Dependent Protein Kinases; D | 2007 |
The possible mechanisms by which phanoside stimulates insulin secretion from rat islets.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cyclic AMP-Dependent Protein Kinases; D | 2007 |
The possible mechanisms by which phanoside stimulates insulin secretion from rat islets.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cyclic AMP-Dependent Protein Kinases; D | 2007 |
The possible mechanisms by which phanoside stimulates insulin secretion from rat islets.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cyclic AMP-Dependent Protein Kinases; D | 2007 |
The possible mechanisms by which phanoside stimulates insulin secretion from rat islets.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cyclic AMP-Dependent Protein Kinases; D | 2007 |
The possible mechanisms by which phanoside stimulates insulin secretion from rat islets.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cyclic AMP-Dependent Protein Kinases; D | 2007 |
The possible mechanisms by which phanoside stimulates insulin secretion from rat islets.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cyclic AMP-Dependent Protein Kinases; D | 2007 |
The possible mechanisms by which phanoside stimulates insulin secretion from rat islets.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cyclic AMP-Dependent Protein Kinases; D | 2007 |
The possible mechanisms by which phanoside stimulates insulin secretion from rat islets.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cyclic AMP-Dependent Protein Kinases; D | 2007 |
Glucose-induced insulin release by pancreatic islets is enhanced in rats with naturally occurring obese non-insulin-dependent diabetes.
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diazoxide; Diuretics; Glucose; Glucose Tolera | 1995 |
Prophylaxis of genetically determined diabetes by diazoxide: a study in a rat model of naturally occurring obese diabetes.
Topics: Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diazoxide; Di | 1995 |
Impaired coupling of glucose signal to the exocytotic machinery in diabetic GK rats: a defect ameliorated by cAMP.
Topics: Animals; Arginine; Calcium; Cells, Cultured; Colforsin; Cyclic AMP; Diabetes Mellitus, Type 2; Diazo | 1996 |
The riddle of formycin A insulinotropic action.
Topics: Adenosine; Animals; Calcium; Diabetes Mellitus, Type 2; Diazoxide; Female; Formycins; Glucose; Glybu | 1996 |
Defective insulin secretion in the GK rat is not linked to excessive B-cell stimulation.
Topics: Animals; Diabetes Mellitus, Type 2; Diazoxide; Glucose; Insulin; Insulin Secretion; Islets of Langer | 1997 |
B-cell hyperresponsiveness to glucose in NIDDM during prediabetes.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Diazoxide; Glucose; Islets of Langerhans; Male; | 1997 |
Insulin occludes leptin activation of ATP-sensitive K+ channels in rat CRI-G1 insulin secreting cells.
Topics: Adenosine Triphosphate; Androstadienes; Animals; Binding, Competitive; Chromones; Diabetes Mellitus, | 1998 |
Enhancing effects of long-term elevated glucose and palmitate on stored and secreted proinsulin-to-insulin ratios in human pancreatic islets.
Topics: Adult; Cells, Cultured; Culture Media; Diabetes Mellitus, Type 2; Diazoxide; Glucose; Humans; Insuli | 1999 |
Management of sulfonylurea ingestions.
Topics: Antidotes; Child; Diabetes Mellitus, Type 2; Diazoxide; Gastrointestinal Agents; Glucose; Humans; Hy | 1999 |
Defective stimulus-secretion coupling in islets of Psammomys obesus, an animal model for type 2 diabetes.
Topics: Animals; Colforsin; Diabetes Mellitus, Type 2; Diazoxide; Disease Models, Animal; Disease Susceptibi | 2001 |
A novel enhancer of insulinotrophic action by high glucose (JTT-608) stimulates insulin secretion from pancreatic beta-cells via a new cellular mechanism.
Topics: Animals; ATP-Binding Cassette Transporters; Binding, Competitive; Butyrates; Calcium; Calcium Channe | 2001 |
Vascular K(ATP) channel blockade by glibenclamide, but not by acarbose, in patients with Type II diabetes.
Topics: Acarbose; Acetylcholine; Cross-Over Studies; Diabetes Mellitus, Type 2; Diazoxide; Dipyridamole; Dou | 2002 |
Post-receptor insulin resistance after diazoxide in non-insulin dependent diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diazoxide; Fatty Acids, Nonesterified; Female | 1986 |